Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOryx International Growth Regulatory News (OIG)

Share Price Information for Oryx International Growth (OIG)

Share Price is delayed by 15 minutes
Get Live Data
1,280.00    5.00 (0.39%)
Bid:
1,230.00
Ask:
1,305.00
Spread: 75.00 (6.098%)
Market Cap: £179.20m
OIG Live PriceLast checked at - London Stock Exchange

Intraday Oryx International Growth Share Chart

Interim Management Statement

8 Aug 2011 11:45

RNS Number : 9283L
Oryx International Growth Fund Ld
08 August 2011
 

ORYX INTERNATIONAL GROWTH FUND LIMITED

 8 August 2011

 INTERIM MANAGEMENT STATEMENT FOR THE QUARTER ENDED 30 JUNE 2011

Oryx International Growth Fund Limited ("Oryx" or the "Company"), is publishing this Interim Management Statement in accordance with DTR 4.3 of the FSA Handbook.

This interim management statement has been produced solely to provide additional information to shareholders as a body to meet the relevant requirements of the UK Listing Authority's Disclosure and Transparency Rules. It should not be relied upon by any other party or for any other purpose.

This interim management statement relates to the period from 1 April 2011 to 30 June 2011, and contains information that covers this period, and up to the date of publication of this interim management statement, unless otherwise specified.

 Manager's Review

Markets drifted for the majority of the period under review with the FTSE Small Cap TR Index up 0.7% and the FTSE All-Share TR Index (£) down 0.9%. It is pleasing to report that against this backdrop the net asset value rose by 8.8% to 296p per share. The increase in the portfolio was broadly based, although there was no movement in the value of the unquoted portfolio. Whilst current market conditions are difficult the manager believes there is inherent value in the portfolio which will be realised in the next quarter.

Material TransactionsSince 1 April 2011 the Company has purchased for cancellation the following shares:

15 April 2011 a total of 250,000 ordinary shares at a gross price of £2.30 per share.27 May 2011 a total of 170,000 ordinary shares at a gross price of £2.30 per share.

Material EventsThere were no material events during the quarter ended 30 June 2011.

Report and AccountsOn 30 June 2011, the Company posted its Annual Report for the year ended 31 March 2011 to Shareholders together with a circular containing the Notice convening the Company's AGM at 11am on 12 August 2011 and details of a proposed waiver of the Rule 9 provisions of the City Code on Takeovers and Mergers.

 

Financial Highlights

 

 

30 June 2011

31 March 2011

31 December 2010

30 June 2010

 

 

 

 

 

NAV

£2.96

£2.72

£2.81

£2.35

 

 

 

 

 

US Dollar / Sterling Exchange Rate

 1.6055

 1.6029

 1.5657

 1.4961

 

 

 

 

 

 

 

Twenty Largest Equity Investments at 30 June 2011

 

% Net Assets

RPC Group Plc

7.60

CVS Group Plc

7.01

Guinness Peat Group Plc

6.72

BBA Aviation Plc

6.38

Gleeson (M.J.) Group Plc

6.11

Augean

5.34

Orthoproducts Ltd

4.68

Quarto Group Inc

4.54

GTL Resources Plc

4.19

Bavaria Industriekapital AG

4.02

Idox Plc

3.92

Sinclair Pharma Plc

3.51

Innovation Group Plc

3.39

Catalyst Media Group Plc

3.38

Redhall Group Plc

3.21

Journey Group Plc

2.99

Nastor Inv Ltd Zero Redeem Prefer Shares

2.38

Bionostics Holdings Ltd

2.19

Green Co2 Plc

2.13

Celsis AG

1.64

85.33

 

The financial information for the quarter ended 30 June 2011 contained within this Interim Management Statement has not been audited.

By order of the Board

BNP Paribas Fund Services (Guernsey) Limited, for and on behalf ofOryx International Growth Fund Limitedas Company Secretary

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUGUUPRUPGGUR
Date   Source Headline
10th Aug 202310:44 amRNSNet Asset Value(s)
2nd Aug 20237:00 amRNSHolding(s) in Company
26th Jul 20234:00 pmRNSNotice of AGM
11th Jul 202311:23 amRNSNet Asset Value(s)
6th Jul 20237:00 amRNSAnnual Financial Report
14th Jun 20239:25 amRNSDirector Declaration
8th Jun 20234:11 pmRNSNet Asset Value(s)
8th Jun 20238:59 amRNSDirector Declaration
11th May 20234:46 pmRNSNet Asset Value(s)
14th Apr 20239:08 amRNSNet Asset Value(s)
9th Mar 202310:30 amRNSPrevious Shareholding in WANdisco plc
7th Mar 20235:24 pmRNSNet Asset Value(s)
9th Feb 20239:49 amRNSNet Asset Value(s)
26th Jan 20234:40 pmRNSSecond Price Monitoring Extn
26th Jan 20234:35 pmRNSPrice Monitoring Extension
20th Jan 20234:40 pmRNSSecond Price Monitoring Extn
20th Jan 20234:35 pmRNSPrice Monitoring Extension
19th Jan 202310:04 amRNSDirector/PDMR Shareholding
13th Jan 20234:02 pmRNSDirector/PDMR Shareholding
11th Jan 202312:11 pmRNSNet Asset Value(s)
13th Dec 202211:36 amRNSNet Asset Value(s)
9th Dec 20227:00 amRNSHalf-year Report
10th Nov 202210:01 amRNSNet Asset Value(s)
24th Oct 20225:26 pmRNSTR1: Notification of major holdings
12th Oct 20229:30 amRNSNet Asset Value(s)
3rd Oct 20227:00 amRNSTotal Voting Rights
16th Sep 20227:00 amRNSDirectorate Change
12th Sep 20224:40 pmRNSSecond Price Monitoring Extn
12th Sep 20224:36 pmRNSPrice Monitoring Extension
9th Sep 202212:49 pmRNSNet Asset Value(s)
18th Aug 202210:31 amRNSResult of Annual General Meeting
9th Aug 202212:56 pmRNSNet Asset Value(s)
15th Jul 20224:45 pmRNSNotice of AGM
12th Jul 202212:27 pmRNSNet Asset Value(s)
8th Jul 20227:00 amRNSAnnual Financial Report
6th Jul 20225:07 pmRNSHolding(s) in Company
23rd Jun 20222:30 pmRNSHolding(s) in Company
22nd Jun 20225:04 pmRNSHolding(s) in Company
15th Jun 202212:21 pmRNSNet Asset Value(s)
12th May 202212:51 pmRNSNet Asset Value(s)
28th Apr 20225:39 pmRNSHolding(s) in Company
11th Apr 20222:13 pmRNSNet Asset Value(s)
10th Mar 202210:00 amRNSNet Asset Value(s)
9th Feb 20221:10 pmRNSNet Asset Value(s)
13th Jan 20221:16 pmRNSNet Asset Value(s)
17th Dec 20217:00 amRNSHalf-Yearly Results
10th Dec 202112:50 pmRNSNet Asset Value(s)
17th Nov 20217:00 amRNSHolding(s) in Company
11th Nov 202112:32 pmRNSNet Asset Value(s)
26th Oct 202111:24 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.